

1 **Title**

2 Estimated Incidence of Respiratory Hospitalizations Attributable to RSV Infections
3 across Age and Socioeconomic Groups

4 **Authors**

5 Zhe Zheng^{1*}, Joshua L. Warren², Eugene D. Shapiro,³
6 Virginia E. Pitzer¹, Daniel M. Weinberger¹

7
8 **Affiliations**

9 ¹Department of Epidemiology of Microbial Diseases and the Public Health Modeling Unit, Yale
10 School of Public Health, New Haven, CT, USA.

11 ²Department of Biostatistics and the Public Health Modeling Unit, Yale School of Public Health,
12 New Haven, CT, USA.

13 ³Department of Pediatrics, Yale School of Medicine, New Haven, CT, USA

14
15 * Corresponding Author:

16 Zhe Zheng,
17 Department of Epidemiology of Microbial Diseases,
18 Yale University,
19 60 College Street, New Haven, Connecticut, USA

20 zhe.zheng@yale.edu,

21 Tel: +1(203)-298-2435

22 Abstract: [word count: 238 words]

23 Background:

24 Surveillance for respiratory syncytial virus (RSV) likely captures just a fraction of the burden of
25 disease. Understanding the burden of hospitalizations and disparities between populations can
26 help to inform upcoming RSV vaccine programs and to improve surveillance.

27 Methods:

28 We obtained monthly age-, ZIP code- and cause-specific hospitalizations in New York, New
29 Jersey, and Washington from the US State Inpatient Databases (2005-2014). We estimated the
30 incidence of respiratory hospitalizations attributable to RSV by age and by socioeconomic status
31 using regression models. We compared the estimated incidence and the recorded incidence
32 (based on ICD9-CM) of RSV hospitalizations to estimate the under-recorded rate in the different
33 sub-populations.

34 Results:

35 The estimated annual incidence of respiratory hospitalizations due to RSV was highest among
36 infants <1 year of age with low socioeconomic status, (2700 per 100,000 people, 95% CrI [2600,
37 2900]) and were considerable in older adults that are ≥ 65 years of age across socioeconomic
38 status, ranging from 130 to 970 per 100,000 people. The incidence of hospitalization recorded as
39 being due to RSV represented a significant undercount, particularly in adults. Only <5% of the
40 estimated RSV hospitalizations were captured for the older adults that are ≥ 65 years of age.

41 Conclusions:

42 RSV causes a considerable burden of hospitalization in young children and in older adults in the
43 U.S, with variation by socioeconomic group. Estimates of the incidence of hospitalizations due
44 to RSV in older adults based on the recorded diagnoses likely represent an underestimate.

45

46 **Key messages**

47 What is already known on this topic?

48 Previous study suggested that the incidence of hospitalization for bronchiolitis (often caused by
49 RSV) in infants varies greatly between communities of different socioeconomic levels. However,
50 it is unclear whether these differences are associated with the admission criteria or the risk of
51 RSV infection.

52 What this study adds?

53 The estimated annual incidence of respiratory hospitalizations due to RSV in infants residing in
54 low socioeconomic areas was about twice as high as the incidence in infants residing in high
55 socioeconomic areas. In older adults, a small fraction of the hospitalizations estimated to be
56 caused by RSV were recorded as such in the inpatient database.

57 How this study might affect research, practice or policy?

58 With several vaccines and extended half-life monoclonal antibodies against RSV under active
59 development, these estimates can help anticipate the impact of RSV prevention strategies in
60 populations of different demographic characteristics.

61 **Introduction**

62 Respiratory syncytial virus (RSV) causes a large burden of disease in infants, young children,
63 and the elderly^{1,2}. Although no vaccine against RSV is currently available, multiple vaccines and
64 extended-duration prophylaxis are in development, and preliminary estimates of their efficacy
65 are promising^{3,4}. To accurately assess the potential impact of interventions against RSV, it is
66 essential to evaluate the health burden of RSV in sub-populations with different demographic
67 and socioeconomic characteristics.

68 Though the epidemic dynamics of RSV vary even within local geographic areas^{5,6}, little is
69 known about how the burden of RSV varies between populations. Previous research has had
70 mixed conclusions about the impact of socioeconomic status (SES) on the risk of RSV infections
71⁷⁻⁹. While some of the studies found lower rates of RSV infection in higher SES groups, others
72 found no relationship. The incidence of hospitalization for bronchiolitis in infants (often caused
73 by RSV) varies greatly between communities of different socioeconomic levels¹⁰⁻¹².

74 Rates of hospitalizations recorded as being due to RSV infections can also be influenced by
75 testing and coding practices. RSV-associated hospitalizations are likely under-ascertained using
76 laboratory surveillance data. The decision to conduct a diagnostic test for RSV infection and the
77 sensitivity of the tests can influence the completeness of detection. For instance, compared with
78 children, adults are less likely to be tested for RSV, and the diagnostic tests have lower
79 sensitivity in adults^{13,14}.

80 The goal of this study was to quantify the annual incidence of hospitalizations associated with
81 RSV in different localities and to estimate the degree of under-recording between sub-

82 populations in different localities. To achieve this, we fitted regression models to time series data
83 from comprehensive hospitalization databases from three states in the United States (US) to
84 estimate variations in RSV-attributable incidence of respiratory hospitalizations. Our results can
85 be used to improve RSV surveillance and to inform the potential impacts of different strategies
86 to prevent RSV infections.

87 **Materials and Methods**

88 *Overview*

89 We used hierarchical Bayesian regression models to estimate the incidence of respiratory
90 hospitalizations attributable to RSV infections in different age and SES groups. The model
91 incorporated monthly data on the number of hospitalizations recorded as due to RSV infections
92 (based on ICD-9-CM) while adjusting for influenza infections, seasonality and underlying
93 temporal trends. The goal of these analyses was to link variations in the number of
94 hospitalizations recorded as due to RSV infections with variations in the number of all-cause
95 respiratory hospitalizations¹⁵⁻¹⁸.

96 *Data sources*

97 Data consisting of individual-level hospital discharges from the states of New York, New Jersey,
98 and Washington from July 2005 to June 2014 were obtained from the State Inpatient Databases
99 of the Healthcare Cost and Utilization Project, maintained by the Agency for Healthcare
100 Research and Quality (purchased through the HCUP Central Distributor)¹⁹. Variables included
101 age at admission, ZIP code of residence, the recorded ICD-9-CM-diagnoses (multiple fields),

102 and the month and the year of hospital admission. The outcome in the regression was the number
103 of hospital discharges for respiratory causes by age, month, and SES classification of ZIP code
104 of residence based on median household income at the ZIP-code level. Respiratory
105 hospitalizations were defined as an ICD-9-CM code in the range 460-519 in any of the diagnosis
106 fields (including hospitalizations with diagnoses of pneumonia, bronchitis, and chronic lower
107 respiratory disease (CLRD), etc.). We analyzed hospitalizations in 9 age categories (<1, 1, 2-4,
108 5-9, 10-19, 20-44, 45-64, 65-84, 85+ years).

109 Median household income at the ZIP-code level was obtained from the US Census Bureau's
110 American Community Survey. Our analyses were based on the median household income for
111 2006-2011. We grouped the ZIP codes into three distinctive SES groups based on the tertile of
112 income. ZIP codes were assigned to the same SES group for the entire period. Population
113 estimates for each ZIP code and age group were obtained from the US Bureau of the Census for
114 the year 2010²⁰.

115 The indicator of RSV infections in all age groups was defined as the monthly RSV-specific
116 hospitalizations count (ICD-9-CM code: 079.6, 466.11, 480.1) among children under two years
117 of age in the same SES group. We used RSV infections among children under two years of age
118 as the marker for RSV infections because previous research has shown detection of RSV in
119 children is more accurate than detection in adults^{21 22}. Similarly, to form a more reliable
120 indicator of influenza infections, we aggregated the influenza-specific hospitalizations count
121 (ICD-9-CM code: 487) across age groups in the same SES group.

122 Time series of monthly count were created for each income level and age group based on the
123 date of hospital admission for either RSV infections or influenza infections and age
124 category. Data cleaning was performed with SAS software, version 9.2 (SAS Institute, Cary,
125 North Carolina). Statistical analyses were performed in R v4.0.2.

126 *Statistical model*

127 We estimated the age- and SES-specific incidence of respiratory hospitalizations attributable to
128 RSV using hierarchical Bayesian regression models. The model had a negative binomial
129 likelihood and identity link. The hierarchical structure provides advantages compared with fitting
130 these models individually by group. The model pools information across all groups leading to a
131 reduction in uncertainty during parameter estimation while still allowing for differences between
132 groups²³. The identity link ensures that each covariate has an additive, rather than a
133 multiplicative, effect on the outcomes of interest^{24 25}. Monthly and yearly dummy variables were
134 used to adjust for seasonality and temporal trends, respectively. Our model used seasonal dummy
135 variables instead of polynomial time trends or sinusoidal curves because the seasonal dummy
136 variable resulted in significantly improved model fit as measured by deviance information
137 criterion (DIC) (Table S1)^{17 18 26}. Details on the model structure can be found in the
138 supplementary document with code available via GitHub
139 (https://github.com/Weinbergerlab/RSVhospitalizations_USA/blob/main/RSV_burden.Rmd).

140 After we fitted the model, the estimated “true” number of hospitalizations attributable to RSV
141 infections for each time point and stratum was estimated by multiplying posterior samples of the
142 age-specific scaling factor by the count of monthly hospitalizations that were recorded as due to

143 RSV infections among children under 2 years of age in the same SES group. The average annual
144 incidence of hospitalizations attributable to RSV infections was estimated by dividing the sum of
145 the group-specific estimated number of hospitalizations attributable to RSV infections over nine
146 epidemiologic years by the age- and site-specific population. The recording ratios were
147 calculated by dividing the number of recorded ICD-9-CM diagnoses for RSV in each age and
148 SES group by the modeled estimates in the same group. The attributable percent of RSV was
149 calculated by dividing the sum of the estimated number of respiratory hospitalizations
150 attributable to RSV infections by the sum of the model-predicted number of all-cause respiratory
151 hospitalizations in each age and SES group over the entire study period. (Note that model-
152 predicted number of all-cause respiratory hospitalizations and recorded number of all-cause
153 respiratory hospitalizations in each group were almost identical; The model captured 99.98% of
154 the variability in the recorded respiratory hospitalizations in each group.) For each measure, we
155 obtained and summarized samples from the posterior distributions of interest. The incidence was
156 rounded to two significant figures. The recording ratios and attributable percent were rounded to
157 the nearest whole number.

158 **Results**

159 *Recorded hospitalizations*

160 From July 2005 through June 2014, there were a total of 9,418,390 hospitalizations for
161 respiratory illnesses that contained detailed age and ZIP code information across the three states.
162 Age or ZIP code were missing for 0.1% of the records in the database, and these records were
163 excluded. There were 66,679 hospitalizations recorded as being due to RSV infections among

164 children under two years of age during the study period. State-specific information can be found
165 in the supplementary document (Table S1).

166 *Estimates of RSV-Associated Respiratory Hospitalizations*

167 The highest estimated incidence of hospitalizations attributable to RSV infections was found in
168 infants <1 year of age (2800 per 100,000 people, 95% CrI [2600, 2900]), followed by children 1-
169 2 years of age (930 per 100,000 people, 95% CrI [830, 1000]) and by adults ≥ 85 years of age
170 (970 per 100,000 people, 95% CrI [680, 1300]) (**Figure 1**). The estimated hospitalization
171 incidence for RSV infections among children in the ZIP codes from the lowest tertile for SES
172 was almost double that of children in the highest SES ZIP codes (**Figure 1**). Analyzing the data
173 from each state separately yielded similar results (see Figure S1-S3).

174 *Gap between recorded and estimated RSV hospitalizations*

175 The estimated proportion of hospitalizations caused by RSV that were recorded as being due to
176 RSV was similar between SES groups and decreased with age (Figure 2). For example, in the
177 highest SES group, 72% (95% CrI: 69%-76%) of estimated RSV hospitalizations among infants
178 under 1 year of age were recorded as being caused by RSV, whereas only 3% (95% CrI: 2%-5%)
179 of hospitalizations estimated to be due to RSV among adults ≥ 85 years of age were recorded as
180 due to RSV.

181 While most of the estimated hospitalizations attributable to RSV infections among adults ≥ 65
182 years of age were not recorded as being due to RSV, the rate of recording increased over time
183 (Figure 3). The estimated recording ratio was 1% (95% CrI: 1%-1%) in January (peak time of

184 RSV epidemics) during the 2005-2006 RSV season and increased to 12% (95% CrI: 9%-18%) in
185 January during the 2013-2014 RSV season.

186 *Percent of respiratory hospitalizations attributable to RSV*

187 Infections due to RSV were estimated to contribute to a large proportion of hospitalizations for
188 respiratory illnesses in young children (Figure 4). On average, 45% (95% CrI: 42%-47%) of such
189 hospitalizations were attributable to RSV infection in infants <1 year of age. This proportion was
190 smaller in older age groups (Table 1). For example, in adults 20-44 years of age, only 1% (95%
191 CrI: 0%-2%) of hospitalizations for respiratory infections were attributable to RSV infection.
192 The attributable percent was similar across SES levels.

193 **Discussion**

194 Understanding the incidence of hospitalizations caused by RSV can help to anticipate the
195 potential impacts of upcoming RSV vaccine programs in different sub-populations. In addition,
196 information about the differences in recording ratios between subpopulations may help increase
197 awareness of providers about testing RSV in older adults and may lead to an improvement of
198 RSV surveillance. We estimated a considerable burden of disease in young children (<5 years of
199 age) and in the elderly (≥ 65 years of age). The estimated incidence of hospitalizations due to
200 RSV was notably higher among patients from low SES ZIP codes. RSV was less likely to be
201 diagnosed in older adults. The percentage of hospitalizations for respiratory illnesses attributable
202 to RSV was highest in infants and lowest among adults 20-64 years of age. With several
203 vaccines and monoclonal antibodies against RSV under active development, these estimates can
204 help to guide estimates of the impact of these interventions in different populations.

205 Our age-based estimates for the incidence and attributable percent of hospitalizations due to RSV
206 infections are consistent with previous studies^{18 27 28}. The statistical models we used in our
207 analysis are an extension of the commonly employed time series models that estimate rates of
208 respiratory virus-associated hospitalization^{15 29}. By modifying the model structure, our study
209 provides new insights into the variation in RSV-associated respiratory hospitalizations by SES
210 groups. Our estimates of the incidence of hospitalizations attributable to RSV infections among
211 infants <1 year of age are lower than the average incidences in published estimates in the more
212 distant past, but comparable to the averages in recent years^{18 27}.

213 Our estimates suggest that the incidence of hospitalizations caused by RSV has been under-
214 recorded in the older adults. The substantial estimated incidence of hospitalizations attributable
215 RSV among those aged 65 and older agrees with earlier observations in a cohort study and time-
216 series study, both of which showed that the incidence of hospitalizations attributable RSV is
217 heavily skewed toward the older adults^{30 27}. This age group should be considered as a potential
218 target population for RSV vaccines due to the potential high case-fatality rate after RSV
219 infection^{30 31}. The number of hospitalizations recorded as being caused by RSV increased over
220 the study period in the patients 65 years of age and older. This trend may reflect changes in
221 testing practices among older adults over time. To understand the actual incidence of
222 hospitalizations attributable RSV in the elderly, more frequent testing for RSV infections is
223 needed.

224 Our results indicate that children in low-SES communities suffer from a particularly high
225 incidence of RSV-associated hospitalizations. There are a number of potential causes for this
226 disparity, including factors that might influence risk of viral infection, such as family size and

227 the number of contacts; exposure to tobacco smoke and other pollutants; high prevalence of
228 underlying respiratory diseases like asthma and chronic lung disease from prematurity; and
229 duration of breastfeeding^{32,33}. Additionally, decisions to for admit patients could be influenced
230 by the family's SES and may vary based on factors such as the co-morbid illnesses of the
231 patients, the reliability of follow-up, and the practices of individual clinicians.

232 Our results suggest that about 45% of hospitalizations for respiratory illnesses in infants <1 year
233 old are attributable to RSV infections (approximately 20 of 1000 infants/year). Monoclonal
234 antibodies against RSV with an extended half-life³⁴, as well as vaccination of mothers and direct
235 vaccination of infants using live-attenuated vaccines, might help to reduce the incidence of RSV
236 infections³¹.

237 There are several caveats to our results. First, we used hospitalizations due to RSV infections
238 among children <2 years of age as a proxy for the timing of RSV infections in the entire
239 population. However, there may be differences in the timing of infections among the various age
240 groups. In our preliminary analyses, we tested different time lags between the various age groups,
241 but it did not improve our model fit. Since our model used monthly inpatient data, minor
242 differences in timing between age groups were less likely to be a factor. Second, the
243 cocirculation of other respiratory viruses may confound our estimates. We may overestimate
244 hospitalizations attributable to RSV by not including infections due to respiratory viruses other
245 than influenza and RSV as covariates. However, previous studies indicated that most other
246 respiratory viruses do not have the same timing as epidemics of RSV infections³⁵⁻³⁷. Therefore,
247 the cocirculation of other respiratory viruses should have a relatively small impact on our
248 estimates of RSV-attributable hospitalizations. Third, the estimates of recording ratios rely on the

249 validity of estimates of the incidence of RSV-attributable hospitalizations. Since there is no gold
250 standard of estimates of RSV-attributable hospitalizations, it is hard to validate our estimates.
251 Still, our age-based estimates of recording ratios are similar to those in a previous study
252 conducted by the Centers for Disease Control and Prevention ²⁷.

253 In conclusion, children in families residing in low-SES areas had the highest incidence of RSV-
254 associated hospitalizations for respiratory illnesses. The incidence of hospitalizations for RSV
255 infections in the older adults is greatly under-recorded. More comprehensive testing for RSV
256 among older adults might help to better define this problem. Vaccines against RSV might
257 provide substantial benefit to young children and to the older adults.

258 **Conflict of Interest**

259 VEP has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input
260 Engagements on respiratory syncytial virus. DMW has received consulting fees from Pfizer,
261 Merck, GSK, Affinivax, and Matrivax for work unrelated to this manuscript and is Principal
262 Investigator on research grants from Pfizer and Merck on work unrelated to this manuscript. All
263 other authors report no relevant conflicts.

264

265 **Funding**

266 Research reported in manuscript was fully supported by the National Institute of Allergy and
267 Infectious Diseases (MIDAS Program) of the National Institutes of Health under award number
268 R01AI137093. The content is solely the responsibility of the authors and does not necessarily
269 represent the official views of the National Institutes of Health.

270

271 **Author contributions**

272 ZZ implemented the study, analyzed the data and drafted the article. JLW designed the study's
273 analytic strategy and helped prepare the Methods sections of the text. EDS helped revise the
274 study design and manuscript for important intellectual content. VEP conceptualized the study
275 and consulted on the analyses and revisions of the manuscript. DMW conceptualized and
276 designed the study, and reviewed and revised the manuscript. All authors have seen and
277 approved the final draft of the manuscript.

278

279 **Acknowledgments**

280 The authors thank Dr. Louis Bont for constructive discussion that help the authors improve the
281 manuscript.

282

283 **References:**

- 284 1. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young
285 children. *The New England journal of medicine* 2009;**360**(6):588-98.
- 286 2. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute
287 lower respiratory infections due to respiratory syncytial virus in young children in 2015: a
288 systematic review and modelling study. *Lancet* 2017;**390**(10098):946-58.
- 289 3. PATH. RSV Vaccine and mAb Snapshot. Secondary RSV Vaccine and mAb Snapshot April 2021.
290 <https://path.org/resources/rsv-vaccine-and-mab-snapshot/>.
- 291 4. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. *The New England journal of*
292 *medicine* 2020;**383**(7):698.
- 293 5. Zheng Z, Pitzer VE, Warren JL, et al. Community factors associated with local RSV epidemic patterns: a
294 spatiotemporal modeling study. *medRxiv* 2020:2020.07.06.20144345.
- 295 6. Noveroske DB, Warren JL, Pitzer VE, et al. Local variations in the timing of RSV epidemics. *BMC*
296 *infectious diseases* 2016;**16**(1):674.
- 297 7. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower
298 respiratory tract disease. *The Journal of pediatrics* 2003;**143**(5 Suppl):S118-26.
- 299 8. Homaira N, Mallitt KA, Oei JL, et al. Risk factors associated with RSV hospitalisation in the first 2 years
300 of life, among different subgroups of children in NSW: a whole-of-population-based cohort
301 study. *BMJ open* 2016;**6**(6):e011398.
- 302 9. Holmen JE, Kim L, Cikesh B, et al. Relationship between neighborhood census-tract level
303 socioeconomic status and respiratory syncytial virus-associated hospitalizations in U.S. adults,
304 2015-2017. *BMC infectious diseases* 2021;**21**(1):293.
- 305 10. Lewis KM, De Stavola B, Hardelid P. Geospatial and seasonal variation of bronchiolitis in England: a
306 cohort study using hospital episode statistics. *Thorax* 2020;**75**(3):262-68.
- 307 11. Green CA, Yeates D, Goldacre A, et al. Admission to hospital for bronchiolitis in England: trends over
308 five decades, geographical variation and association with perinatal characteristics and
309 subsequent asthma. *Archives of disease in childhood* 2016;**101**(2):140-6.
- 310 12. Cheung CR, Smith H, Thurland K, et al. Population variation in admission rates and duration of
311 inpatient stay for bronchiolitis in England. *Archives of disease in childhood* 2013;**98**(1):57-9.
- 312 13. Lee N, Walsh EE, Sander I, et al. Delayed Diagnosis of Respiratory Syncytial Virus Infections in
313 Hospitalized Adults: Individual Patient Data, Record Review Analysis and Physician Survey in the
314 United States. *The Journal of infectious diseases* 2019;**220**(6):969-79.
- 315 14. Talbot HK, Falsey AR. The diagnosis of viral respiratory disease in older adults. *Clinical infectious*
316 *diseases : an official publication of the Infectious Diseases Society of America* 2010;**50**(5):747-51.
- 317 15. Taylor S, Taylor RJ, Lustig RL, et al. Modelling estimates of the burden of respiratory syncytial virus
318 infection in children in the UK. *BMJ open* 2016;**6**(6):e009337.
- 319 16. Simonsen L, Blackwelder WC, Reichert TA, et al. Estimating deaths due to influenza and respiratory
320 syncytial virus. *JAMA* 2003;**289**(19):2499-500; author reply 500-2.
- 321 17. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations Associated With Influenza and Respiratory
322 Syncytial Virus in the United States, 1993-2008. *Clinical Infectious Diseases* 2012;**54**(10):1427-36.
- 323 18. Goldstein E, Greene SK, Olson DR, et al. Estimating the hospitalization burden associated with
324 influenza and respiratory syncytial virus in New York City, 2003-2011. *Influenza and other*
325 *respiratory viruses* 2015;**9**(5):225-33.
- 326 19. Healthcare Cost and Utilization Project State Inpatient Databases. Agency for Healthcare Research
327 and Quality. Secondary Healthcare Cost and Utilization Project State Inpatient Databases.
328 Agency for Healthcare Research and Quality 2014. [http://www.hcup-](http://www.hcup-us.ahrq.gov/sidoverview.jsp)
329 [us.ahrq.gov/sidoverview.jsp](http://www.hcup-us.ahrq.gov/sidoverview.jsp).

- 330 20. American Community Survey 1-Year Data (2005-2019). United States Census Bureau. Secondary
331 American Community Survey 1-Year Data (2005-2019). United States Census Bureau.
332 <https://www.census.gov/data/developers/data-sets/acs-1year.2010.html>.
- 333 21. Casiano-Colón AE, Hulbert BB, Mayer TK, et al. Lack of sensitivity of rapid antigen tests for the
334 diagnosis of respiratory syncytial virus infection in adults. *Journal of Clinical Virology*
335 2003;**28**(2):169-74.
- 336 22. Allen KE, Chommanard C, Haynes AK, et al. Respiratory syncytial virus testing capabilities and
337 practices among National Respiratory and Enteric Virus Surveillance System laboratories, United
338 States, 2016. *Journal of clinical virology : the official publication of the Pan American Society for*
339 *Clinical Virology* 2018;**107**:48-51.
- 340 23. Bolker BM, Brooks ME, Clark CJ, et al. Generalized linear mixed models: a practical guide for ecology
341 and evolution. *Trends Ecol Evol* 2009;**24**(3):127-35.
- 342 24. Gay NJ, Andrews NJ, Trotter CL, et al. Estimating deaths due to influenza and respiratory syncytial
343 virus. *JAMA* 2003;**289**(19):2499; author reply 500-2.
- 344 25. Goldstein E, Viboud C, Charu V, et al. Improving the estimation of influenza-related mortality over a
345 seasonal baseline. *Epidemiology* 2012;**23**(6):829-38.
- 346 26. Widmer K, Zhu Y, Williams JV, et al. Rates of hospitalizations for respiratory syncytial virus, human
347 metapneumovirus, and influenza virus in older adults. *The Journal of infectious diseases*
348 2012;**206**(1):56-62.
- 349 27. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory
350 syncytial virus in the United States, 1993-2008. *Clinical infectious diseases : an official*
351 *publication of the Infectious Diseases Society of America* 2012;**54**(10):1427-36.
- 352 28. Cassell K, Gacek P, Rabatsky-Ehr T, et al. Estimating the True Burden of Legionnaires' Disease.
353 *American journal of epidemiology* 2019;**188**(9):1686-94.
- 354 29. Fleming DM, Taylor RJ, Lustig RL, et al. Modelling estimates of the burden of Respiratory Syncytial
355 virus infection in adults and the elderly in the United Kingdom. *BMC infectious diseases*
356 2015;**15**:443.
- 357 30. Lee N, Lui GC, Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory
358 syncytial virus infections. *Clinical infectious diseases : an official publication of the Infectious*
359 *Diseases Society of America* 2013;**57**(8):1069-77.
- 360 31. PATH. RSV Vaccine and mAb Snapshot. Secondary RSV Vaccine and mAb Snapshot.
361 <https://path.org/resources/rsv-vaccine-and-mab-snapshot/>.
- 362 32. Li R, Darling N, Maurice E, et al. Breastfeeding rates in the United States by characteristics of the
363 child, mother, or family: the 2002 National Immunization Survey. *Pediatrics* 2005;**115**(1):e31-7.
- 364 33. Prevention CfDCa. Cigarette Smoking and Tobacco Use Among People of Low Socioeconomic Status.
365 Secondary Cigarette Smoking and Tobacco Use Among People of Low Socioeconomic Status
366 November 25, 2019. <https://www.cdc.gov/tobacco/disparities/low-ses/index.htm>.
- 367 34. AstraZeneca. Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower
368 respiratory tract infections in healthy infants. Secondary Nirsevimab MELODY Phase III trial met
369 primary endpoint of reducing RSV lower respiratory tract infections in healthy infants.
- 370 35. Byington CL, Ampofo K, Stockmann C, et al. Community Surveillance of Respiratory Viruses Among
371 Families in the Utah Better Identification of Germs-Longitudinal Viral Epidemiology (BIG-LoVE)
372 Study. *Clinical Infectious Diseases* 2015;**61**(8):1217-24.
- 373 36. Price OH, Sullivan SG, Sutterby C, et al. Using routine testing data to understand circulation patterns
374 of influenza A, respiratory syncytial virus and other respiratory viruses in Victoria, Australia.
375 *Epidemiology and infection* 2019;**147**:e221.

376 37. Landes MB, Neil RB, McCool SS, et al. The frequency and seasonality of influenza and other
377 respiratory viruses in Tennessee: two influenza seasons of surveillance data, 2010-2012.
378 Influenza and other respiratory viruses 2013;**7**(6):1122-7.

379

380 **Tables**

381 **Table 1. Estimated Percentage of Respiratory Hospitalizations Attributable to RSV**
 382 **infections, by SES and Age Group, 2005–2014**

Age (in years)	Low SES		Medium SES		High SES	
	Mean	95% CrI	Mean	95% CrI	Mean	95% CrI
<1	44%	(42%, 46%)	46%	(44%, 48%)	46%	(44%, 48%)
1	27%	(24%, 29%)	29%	(25%, 31%)	27%	(24%, 29%)
2-4	18%	(16%, 20%)	21%	(18%, 23%)	18%	(16%, 20%)
5-9	9%	(7%, 11%)	11%	(8%, 13%)	9%	(7%, 11%)
10-19	3%	(2%, 4%)	4%	(2%, 5%)	3%	(2%, 4%)
20-44	1%	(0%, 2%)	1%	(0%, 2%)	1%	(0%, 2%)
45-64	1%	(0%, 2%)	1%	(0%, 2%)	1%	(0%, 2%)
65-84	2%	(1%, 3%)	2%	(1%, 3%)	1%	(1%, 2%)
85+	4%	(3%, 6%)	4%	(2%, 5%)	2%	(1%, 3%)

383

384 **Figure Legends**


385 **Figure 1. Estimated RSV-attributable respiratory hospitalization rates by age and SES**
386 **group, July 2005 - June 2014.** The color texts show the mean estimates of RSV-attributable
387 respiratory hospitalization rates in each age and SES group. The error bars indicate the 95%
388 credible intervals of the estimated RSV-attributable respiratory hospitalization rates. Color blue,
389 yellow, and orange correspond to the estimates in populations from low, medium, and high SES
390 ZIP codes.

391 **Figure 2. Ratio of the number of hospitalizations recorded as being due to RSV and the**
392 **number of estimated RSV hospitalizations, by age and SES group, July 2005 - June 2014.**
393 The size of the circles represents the estimated proportion of hospitalizations caused by RSV that
394 were recorded. The texts show the mean estimates of the recording ratio in each age and SES
395 group. The shaded areas indicate the 95% credible intervals of the reporting ratio. Color blue,
396 yellow, and orange correspond to the estimates in populations from low, medium, and high SES
397 ZIP codes.

398 **Figure 3. Respiratory hospitalizations among older adults, July 2005 - June 2014.** The blue
399 area in the left panel shows the total respiratory hospitalization rate among adults aged 65 and
400 above; the yellow area shows the estimated RSV-associated respiratory hospitalizations in the
401 same age group and the red area shows the hospitalizations recorded as RSV. The right panel
402 zooms in to show the increasing trend of recording RSV diagnoses.


403 **Figure 4. Respiratory hospitalizations in infants <1 year of age, July 2005 - June 2014.** The
404 blue area shows the total respiratory hospitalization rate in infants <1 year of age; the yellow area
405 shows the estimated RSV-associated respiratory hospitalizations in the same age group and the
406 red area shows the hospitalizations recorded as being due to RSV.



Estimated RSV hospitalizations
per 100,000 people



Income level

- Low
- Medium
- High






Hospitalizations per 100,000 children under One

750-
500-
250-
0-

Respiratory Hospitalizations
Total
Estimated RSV
Recorded RSV



2006

2008

2010

2012

2014

Date